The Developmental Funds of the CCSG represent one of the most important components of the Core grant in that they allow the Center director to respond to and provide leadership for the scientific needs and priorities of the Center. We use these funds in several ways. First, 'New Investigator' funds are used together with other Center funds (e.g., gift account) and funds from departments and other Centers to provide attractive recruitment packages for faculty important to the Cancer Center's research enterprise. These recruitments may represent a build-up for a new research initiative or expansion of an existing program or replacement for departing or retiring faculty. We have asked for an increase in this category from $300,000/year to $400,000/year reflecting the increasing costs of recruitment and the excellent 'return' in terms of leadership and grant support by recipients. The second use of these funds is for our 'pilot' grant program which utilizes a University-wide application process with an emphasis on young or new faculty. We fully fund 3 pilot grants annually ($40,000 each) and contribute to 3 other (Core grant - $10,000 and ACS institutional grant - $20,000) in 2 separate annual competitions. Our Scientific Advisory Committee reviews and critiques these applications for Cancer Center research priorities and potential for national funding. The recipients of these funds have an excellent track record of successful grant funding (annual direct of $3.9 million and over $11 million for recipients of the past 4 years) and scientific growth of our programs. In addition to the above, we also have a strategy of funding new developmental shared facilities using developmental funds or Core grant re-budgeting to the developmental fund category. This funding period we funded 3 developmental shared facilities (Small Animal Imaging; DNA Sequencing; and Molecular Biology/Recombinant Protein) using funds re-budgeted from the Shared Facility category as well as initiating our Gene Expression facility out of the gift account (equipment and start-up personnel).

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA013148-35
Application #
7310585
Study Section
Subcommittee G - Education (NCI)
Project Start
Project End
Budget Start
2006-04-01
Budget End
2007-03-31
Support Year
35
Fiscal Year
2006
Total Cost
$504,190
Indirect Cost
Name
University of Alabama Birmingham
Department
Type
DUNS #
063690705
City
Birmingham
State
AL
Country
United States
Zip Code
35294
Van Arsdale, Anne R; Arend, Rebecca C; Cossio, Maria J et al. (2018) Insulin-like growth factor 2: a poor prognostic biomarker linked to racial disparity in women with uterine carcinosarcoma. Cancer Med 7:616-625
Kim, Harrison (2018) Modification of population based arterial input function to incorporate individual variation. Magn Reson Imaging 45:66-71
Leath 3rd, Charles A; Monk, Bradley J (2018) Twenty-first century cervical cancer management: A historical perspective of the gynecologic oncology group/NRG oncology over the past twenty years. Gynecol Oncol 150:391-397
Park, Misun; Yoon, Young Sup (2018) Cardiac Regeneration with Human Pluripotent Stem Cell-Derived Cardiomyocytes. Korean Circ J 48:974-988
Toboni, Michael D; Smith, Haller J; Bae, Sejong et al. (2018) Predictors of Unplanned Reoperation for Ovarian Cancer Patients From the National Surgical Quality Improvement Program Database. Int J Gynecol Cancer 28:1427-1431
Dionne-Odom, J Nicholas; Applebaum, Allison J; Ornstein, Katherine A et al. (2018) Participation and interest in support services among family caregivers of older adults with cancer. Psychooncology 27:969-976
Demark-Wahnefried, Wendy; Schmitz, Kathryn H; Alfano, Catherine M et al. (2018) Weight management and physical activity throughout the cancer care continuum. CA Cancer J Clin 68:64-89
Bandari, Shyam K; Purushothaman, Anurag; Ramani, Vishnu C et al. (2018) Chemotherapy induces secretion of exosomes loaded with heparanase that degrades extracellular matrix and impacts tumor and host cell behavior. Matrix Biol 65:104-118
Gowda, Pramod S; Wildman, Benjamin J; Trotter, Timothy N et al. (2018) Runx2 Suppression by miR-342 and miR-363 Inhibits Multiple Myeloma Progression. Mol Cancer Res 16:1138-1148
Dix, Daniel B; McDonald, Andrew M; Gordetsky, Jennifer B et al. (2018) How Would MRI-targeted Prostate Biopsy Alter Radiation Therapy Approaches in Treating Prostate Cancer? Urology 122:139-146

Showing the most recent 10 out of 747 publications